drugset / Trial / NCT07569744

Resveratrol for Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes

NCT07569744

Completed 48 enrolled Universitas Sriwijaya
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Type 2 diabetes mellitus is associated with endothelial dysfunction, which contributes to increased cardiovascular risk. Chronic hyperglycemia induces oxidative stress and reduces nitric oxide bioavailability, leading to impaired endothelial function. Resveratrol, a natural polyphenol with antioxidant and anti-inflammatory properties, has been shown to improve endothelial function in experimental studies. This randomized controlled trial aims to evaluate the effectiveness of resveratrol supplementation in improving endothelial dysfunction and metabolic control in patients with type 2 diabetes mellitus. Endothelial function will be assessed using flow-mediated dilatation (FMD) of the brachial artery and serum endothelial nitric oxide synthase (eNOS) levels. Metabolic parameters including fasting blood glucose, postprandial glucose, HbA1c, and lipid profile will also be evaluated.

Timeline

Start
2026-05-01
Primary completion
2026-06-01
Completion
2026-06-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Resveratrol Small molecule 50 mg Oral